<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>KRAS genotyping is mandatory before anti-epidermal growth factor receptor monoclonal antibody therapy in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>, which is the second leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>death</z:hpo> in the United States and in Europe </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We report our experience of routine KRAS/BRAF mutation screening practice performed on 1130 formalin-fixed paraffin-embedded <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples from 992 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>DNA was extracted from macrodissected <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> areas highlighted by a pathologist, KRAS codons 12/13 and BRAF V600E mutations were assessed in a single SNaPshotÂ® multiplex assay and each mutation was confirmed by an independent analysis </plain></SENT>
<SENT sid="4" pm="."><plain>KRAS and BRAF mutations were, respectively, present in 41.8 and 6.5% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples </plain></SENT>
<SENT sid="5" pm="."><plain>If KRAS and BRAF mutations were mutually exclusive, four samples presented two concomitant KRAS mutations </plain></SENT>
<SENT sid="6" pm="."><plain>Genotyping of paired <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from 44 patients indicated that 5 patients (11.4%) presented discordant KRAS mutational status </plain></SENT>
<SENT sid="7" pm="."><plain>KRAS genotype <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> was also observed within <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> sites in seven cases </plain></SENT>
<SENT sid="8" pm="."><plain>Non-reproducible KRAS artefactual mutations were detected in 53 samples (4.7%) </plain></SENT>
<SENT sid="9" pm="."><plain>We found that the prominent mechanism leading to these artefactual mutations was the fragmentation of DNA occurring during tissue processing </plain></SENT>
<SENT sid="10" pm="."><plain>Routine KRAS genotyping performed on formalin-fixed paraffin-embedded tissues requires, therefore, the development of quality control scheme for molecular pathology, especially because of DNA damages induced by formalin fixation </plain></SENT>
<SENT sid="11" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> observed in some patients indicates that it should be more appropriate to perform KRAS genotyping on <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> if sample is available </plain></SENT>
</text></document>